Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2021-02-04
Last updated
2026-07-14

Condition(s) studied

Acute Respiratory Distress SyndromeExtracorporeal Membrane Oxygenation

Investigational drug(s) / intervention(s)

ECMO supportPROSpect protocolized therapies

ECMO support: ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.

PROSpect protocolized therapies: PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure. The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine.

Study summary

ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.

The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

Eligibility

Sex
ALL
Min age
14 Days
Max age
20 Years
Healthy volunteers
No
Inclusion Criteria: * Time between intubation and ECMO cannulation is less than 240 hours (10 days) * ECMO support type is respiratory (VV or VA cannulation) * Chest radiograph with bilateral lung disease * Moderate or severe pediatric ARDS as measured by oxygenation index or oxygen saturation index after intubation and prior to ECMO cannulation: One OI ≥ 16 or Two OIs ≥ 12 and ≤ 16 at least four hours apart or Two OSIs ≥ 10 at least four hours apart or One OI ≥ 12 and ≤ 16 and One OSI ≥ 10 at least four hours apart Exclusion Criteria: * Previously enrolled in PROSpect * Perinatal related lung disease * Congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis * Respiratory failure caused by cardiac failure or fluid overload * Cyanotic congenital heart disease * Cardiomyopathy * Primary pulmonary hypertension (PAH) * Unilateral lung disease * Intubated for status asthmaticus * Obstructive airway disease * Bronchiolitis obliterans * Post hematopoietic stem cell transplant * Post lung transplant * Home ventilator dependent * Neuromuscular respiratory failure * Head trauma: (managed with hyperventilation) * Intracranial bleeding * Unstable spine, femur or pelvic fractures * Acute abdominal process/open abdomen * Family/medical team have decided to not provide full support * Enrolled in interventional clinical trial: not approved for co-enrollment; does not include cancer protocols. * Known pregnancy

Primary outcome measure(s)

  • Change in functional status — baseline and 1 year after pediatric intensive care unit discharge
    This primary natural history outcome is measured among usual care extracorporeal membrane oxygenation (ECMO) patients. This outcome is the change in functional status as measured at baseline and 12 months after pediatric intensive care unit (PICU) discharge. The instrument is the functional status scale score. The baseline measure will be made within 96 hours of ECMO initiation and reflect patient's status in the week prior to ECMO. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
  • Change in health-related quality of life — baseline and 1 year after pediatric intensive care unit discharge
    This primary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate Version 4.0 Pediatric Quality of Life Inventory (PedsQL 4.0) generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.
  • The proportion of children with a new morbidity — baseline and 1 year after pediatric intensive care unit discharge
    This primary natural history outcome is measured among usual care ECMO patients. A new morbidity is defined as a change in the functional status scale score instrument by 3 or more, as previously described. This outcome will report the proportion of children who acquire a new morbidity as measured at baseline and 12 months after PICU discharge. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
  • All-cause mortality at hospital discharge or 90-days — 90 days after the day of illness on which patients from the two cohorts are matched
    This primary comparative short-term outcome is measured among both usual care ECMO and Prone and Oscillation Pediatric Clinical Trial (PROSpect) protocolized therapy groups. The outcome compares the 90-day mortality for matched children in the two groups. The endpoint is 90 days after the day of illness on which patients from the two cohorts are matched or hospital discharge.
  • Comparative change in one-year functional status — baseline and 1 year after pediatric intensive care unit discharge
    This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the functional status as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
  • Comparative change in one-year health-related quality of life — baseline and 1 year after pediatric intensive care unit discharge
    This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the change in the age-appropriate PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.

Trial sites (95)

FacilityCityRegionStatus
Children's of Alabama Birmingham Alabama
Phoenix Children's Hospital Phoenix Arizona
Arkansas Children's Hospital Little Rock Arkansas
Loma Linda University Children's Hospital Loma Linda California
UCLA Mattel Children's Hospital Los Angeles California
Valley Children's Hospital Madera California
UCSF Benioff Children's Hospital Oakland Oakland California
Children's Hospital of Orange County Orange California
Lucile Packard Children's Hospital Stanford Palo Alto California
UCSF Benioff Children's Hospital - San Francisco San Francisco California
Children's Hospital Colorado Aurora Colorado
Connecticut Children's Medical Center Hartford Connecticut
Yale New Haven Children's Hospital New Haven Connecticut
Nemours Children's Hospital, Delaware Wilmington Delaware
UF Health Shands Children's Hospital Gainesville Florida
Orlando Health Arnold Palmer Hospital for Children Orlando Florida
Nemours Children's Hospital, Florida Orlando Florida
Children's Healthcare of Atlanta Atlanta Georgia
Kapi'olani Medical Center for Women & Children Honolulu Hawaii
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
Comer Children's Hospital Chicago Illinois
OSF Healthcare Children's Hospital of Illinois Peoria Illinois
Riley Hospital for Children Indianapolis Indiana
University of Iowa Health Care Stead Family Children's Hospital Iowa City Iowa
Norton Children's Hospital Louisville Kentucky
Ochsner LSU Health Shreveport Shreveport Louisiana
Johns Hopkins Children's Center Baltimore Maryland
Boston Children's Hospital Boston Massachusetts
University of Michigan - Mott Children's Hospital Ann Arbor Michigan
Children's Hospital of Michigan Detroit Michigan
Helen DeVos Children's Hospital Grand Rapids Michigan
Children's Minnesota Hospital Minneapolis Minnesota
Mayo Eugenio Litta Children's Hospital Rochester Minnesota
Children's Mercy Kansas City Missouri
Cardinal Glennon Children's Hospital St Louis Missouri
St. Louis Children's Hospital St Louis Missouri
Children's Nebraska Omaha Nebraska
UNM Children's Hospital Albuquerque New Mexico
John R. Oishei Children's Hospital Buffalo New York
Hassenfeld Children's Hospital at NYU Langone New York New York

+ 55 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05388708 on ClinicalTrials.gov ↗ ← All trials in Sweden